During the first 4 to 8 weeks, your condition will be monitored to confirm eligibility for the trial. The screening period lasts either 4 weeks if you experience at least 1 confirmed attack, or 8 weeks if you experience at least 2 confirmed attacks.

This period serves to establish your baseline attack rate, which refers to how often you experience episodes of swelling.

You will be randomly assigned to one of two groups. One group will receive ADX-324, which is the medication being tested. The other group will receive a placebo, which is a sterile salt water solution (0.9% sodium chloride) that contains no active medication.

Neither you nor the medical staff will know which treatment you are receiving. This is called a double-blind study design.

You will receive injections under the skin (subcutaneous injections) of either ADX-324 or placebo.

The treatment period will last for 25 weeks.

The injections will be administered according to a schedule determined by the study protocol. The exact frequency of injections will be provided during the trial.

Starting from day 22 of treatment until the week 25 visit, the number and severity of your swelling attacks will be carefully monitored and recorded.

This period is the main evaluation phase where the effectiveness of the treatment is assessed.

You will continue to have access to your usual emergency medication to treat any swelling attacks that occur during the trial. This may include treatments such as C1-inhibitor concentrate (a protein replacement therapy) or bradykinin B2-receptor antagonist (a medication that blocks certain chemical signals causing swelling).

Throughout the 25-week treatment period, you will attend scheduled visits where the medical team will assess your condition.

During these visits, information about any swelling attacks, their severity, and whether you needed emergency medication will be collected.

The medical team will also monitor your safety and any potential side effects from the injections.

At the end of the 25-week treatment period, a final assessment will be conducted.

The total number of swelling attacks you experienced from day 22 to week 25 will be calculated and compared between the treatment groups.

Additional evaluations will include how many attacks required emergency treatment, how many were moderate or severe, and whether you remained free of attacks during the monitoring period.